Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lessons from MATRICS.

Literature DB >> 21325472

Lessons from MATRICS.

Stephen R Marder.

Abstract

Mesh：

Substances：

Year: 2011 PMID： 21325472 PMCID： PMC3044624 DOI： 10.1093/schbul/sbq166

Source DB: PubMed Journal: Schizophr Bull ISSN： 0586-7614 Impact factor: 9.306

× No keyword cloud information.

8 in total

1. Medicine. What are the right targets for psychopharmacology?

Authors: Steven E Hyman; Wayne S Fenton
Journal: Science Date: 2003-01-17 Impact factor: 47.728

2. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project.

Authors: Bruce N Cuthbert; Thomas R Insel
Journal: Schizophr Bull Date: 2010-10-07 Impact factor: 9.306

3. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

Authors: Robert W Buchanan; Miriam Davis; Donald Goff; Michael F Green; Richard S E Keefe; Andrew C Leon; Keith H Nuechterlein; Thomas Laughren; Robert Levin; Ellen Stover; Wayne Fenton; Steve R Marder
Journal: Schizophr Bull Date: 2005-02-16 Impact factor: 9.306

4. The NIMH-MATRICS consensus statement on negative symptoms.

Authors: Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal: Schizophr Bull Date: 2006-02-15 Impact factor: 9.306

5. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

Authors: Michael F Green; Keith H Nuechterlein; Robert S Kern; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112

6. Methodological issues in negative symptom trials.

Authors: Stephen R Marder; David G Daniel; Larry Alphs; A George Awad; Richard S E Keefe
Journal: Schizophr Bull Date: 2011-01-26 Impact factor: 9.306

7. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.

Authors: Deanna M Barch; Cameron S Carter
Journal: Schizophr Res Date: 2005-09-01 Impact factor: 4.939

8. Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Authors: Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Journal: Am J Psychiatry Date: 2008-04-01 Impact factor: 18.112